SEARCH
Quotes News NAV
Corporate News  Detailed News Markets  >  Equity  >  Detailed News
Latest News about business and investments.
Your Result on : Equity   |  News | Corporate News | Detailed News
Back
Zydus Lifesciences receives USFDA approval for Apalutamide Tablets, 60 mg
18-Mar-25   19:40 Hrs IST

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada' Tablets, 60 mg).

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.

Apalutamide tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.

Apalutamide tablets had annual sales of USD 1099.8 mn in the United States (IQVIA MAT January 2025).

Powered by Capital Market - Live News